Participant flow

SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes · Source last updated 2023-11-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off Regorafenib Regorafenib: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off

   id

   FG000

   title

   Cohort A: Liposarcoma

2. description

   21 days on and 7 days off Placebo Placebo: 21 days on and 7 days off

   id

   FG001

   title

   Cohort A: Liposarcoma, Placebo

3. description

   Those patients who started on placebo and crossed over to active drug. Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off Regorafenib Regorafenib: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off

   id

   FG002

   title

   Cohort A: Liposarcoma Crossover

4. description

   Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off Regorafenib Regorafenib: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off

   id

   FG003

   title

   Cohort B: Osteosarcoma

5. description

   21 days on and 7 days off Placebo Placebo: 21 days on and 7 days off

   id

   FG004

   title

   Cohort B: Osteosarcoma, Placebo

6. description

   Patients who started on placebo and crossed over to active drug. Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off Regorafenib Regorafenib: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off

   id

   FG005

   title

   Cohort B: Osteosarcoma Crossover

7. description

   Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off Regorafenib Regorafenib: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off

   id

   FG006

   title

   Cohort C: Ewing Sarcoma

8. description

   Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off Regorafenib Regorafenib: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off

   id

   FG007

   title

   Cohort D: Rhabdomyosarcoma

9. description

   Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off Regorafenib Regorafenib: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off

   id

   FG008

   title

   Cohort E: Mesenchymal Chondrosarcoma

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         24

      2. group Id

         FG001

         num Subjects

         9

      3. group Id

         FG002

         num Subjects

         15

      4. group Id

         FG003

         num Subjects

         22

      5. group Id

         FG004

         num Subjects

         9

      6. group Id

         FG005

         num Subjects

         11

      7. group Id

         FG006

         num Subjects

         30

      8. group Id

         FG007

         num Subjects

         10

      9. group Id

         FG008

         num Subjects

         1

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         17

      2. group Id

         FG001

         num Subjects

         1

      3. group Id

         FG002

         num Subjects

         9

      4. group Id

         FG003

         num Subjects

         11

      5. group Id

         FG004

         num Subjects

         3

      6. group Id

         FG005

         num Subjects

         8

      7. group Id

         FG006

         num Subjects

         22

      8. group Id

         FG007

         num Subjects

         6

      9. group Id

         FG008

         num Subjects

         1

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         7

      2. group Id

         FG001

         num Subjects

         8

      3. group Id

         FG002

         num Subjects

         6

      4. group Id

         FG003

         num Subjects

         11

      5. group Id

         FG004

         num Subjects

         6

      6. group Id

         FG005

         num Subjects

         3

      7. group Id

         FG006

         num Subjects

         8

      8. group Id

         FG007

         num Subjects

         4

      9. group Id

         FG008

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

Study enrollment ended early due to slow enrollment.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice